Skip to main content



14-09-2021 | Oncology | News | Article

No new safety signals for neoadjuvant, maintenance atezolizumab in mesothelioma

Neoadjuvant atezolizumab meets researcher-defined safety criteria for use in combination with cisplatin plus pemetrexed and then as postsurgical maintenance therapy for people with resectable malignant pleural mesothelioma.

14-09-2021 | Oncology | News | Article

Flexibility positively impacts lung cancer clinical trial participation in COVID-19 era

Strategies to improve flexibility in clinical trials may improve enrollment rates during and after the COVID-19 pandemic, according to a study presented at the IASLC 2021 World Conference on Lung Cancer.

13-09-2021 | Oncology | News | Article

​​​​​​​Pretreatment ctDNA levels may predict survival in neoadjuvant-treated NSCLC patients

Assessing circulating tumor DNA levels prior to initiating neoadjuvant chemoimmunotherapy for locally advanced non-small-cell lung cancer could help to identify patients likely to derive long-term benefit from treatment, suggest exploratory data.

13-09-2021 | Oncology | News | Article

Atezolizumab plus chemotherapy feasible for NSCLC with brain metastases

Treatment with carboplatin and pemetrexed plus atezolizumab shows promise for people with nonsquamous non-small-cell lung cancer and asymptomatic, untreated brain metastases, phase 2 study findings indicate.

10-09-2021 | Oncology | News | Article

No OS benefit of lurbinectedin plus doxorubicin in relapsed SCLC

The ATLANTIS trial has found no significant overall survival improvement with the combination of lurbinectedin and doxorubicin versus chemotherapy in previously treated patients with small-cell lung cancer.

09-09-2021 | Oncology | News | Article

Durvalumab–tremelimumab plus chemo ‘a potential new first-line option’ for metastatic NSCLC

The addition of durvalumab plus tremelimumab to chemotherapy significantly improves the outcomes of people with untreated metastatic non-small-cell lung cancer, shows the POSEIDON trial.

27-07-2021 | Oncology | News | Article

Quitting smoking after lung cancer diagnosis improves survival outcomes

Smokers who quit after receiving a diagnosis of early-stage non-small-cell lung cancer significantly improve their likelihood of survival relative to those who continue smoking, shows a large prospective cohort study.

14-06-2021 | Oncology | News | Article

Benefit of second-line vinorelbine in malignant mesothelioma shown in VIM trial

Results from the phase 2 VIM trial support the use of vinorelbine in patients with malignant pleural mesothelioma whose disease has progressed following platinum-based therapy.

09-06-2021 | Oncology | News | Article

CheckMate 9LA update shows continued benefit of nivolumab–ipilimumab plus chemo

The addition of nivolumab plus ipilimumab to first-line chemotherapy continues to be beneficial for patients with metastatic non-small-cell lung cancer with longer follow-up, show updated phase 3 trial data.

09-06-2021 | Oncology | News | Article

CheckMate 816 surgical outcomes support neoadjuvant nivolumab in NSCLC

Adding nivolumab to neoadjuvant chemotherapy for resectable non-small-cell lung cancer is not associated with surgical delays or complications, show CheckMate 816 data presented at the 2021 ASCO Annual Meeting.

06-06-2021 | Oncology | News | Article

PACIFIC at 5 years shows ‘robust and sustained’ OS benefit with durvalumab

Five-year findings from the PACIFIC trial for patients with unresectable stage III non-small-cell lung cancer continue to show survival benefits with 1 year of durvalumab therapy versus placebo after platinum-based chemoradiotherapy.

04-06-2021 | Oncology | News | Article

Adjuvant atezolizumab delays recurrence in early-stage NSCLC patients

People with stage II–IIIA non-small-cell lung cancer derive a significant disease-free survival benefit from adjuvant treatment with atezolizumab versus best supportive care, according to phase 3 trial results.

03-06-2021 | Oncology | News | Article

Sotorasib approved for KRAS-mutated NSCLC in USA

More information on this announcement available here

28-05-2021 | Oncology | News | Article

EMA recommends cemiplimab for first-line NSCLC treatment

Read more on this decision here

17-05-2021 | Oncology | News | Article

Nab-paclitaxel offers alternative to docetaxel in pretreated advanced NSCLC

Nab-paclitaxel offers a similar survival benefit to docetaxel when given to previously treated patients with advanced non-small-cell lung cancer, show data from the phase 3 J-AXEL trial.

04-05-2021 | Oncology | News | Article

KEYNOTE-189 final analysis confirms pembrolizumab nonsquamous NSCLC benefits

The addition of pembrolizumab to pemetrexed–paclitaxel chemotherapy provides durable survival advantages for treatment-naïve patients with metastatic, nonsquamous non-small-cell lung cancer, the final protocol-specified analysis of KEYNOTE-189 has confirmed.

29-04-2021 | Oncology | News | Article

Nivolumab–ipilimumab receives nod from EMA for malignant pleural mesothelioma

Click through to read more details

27-04-2021 | Oncology | News | Article

KEYNOTE-158 points to pembrolizumab potential in advanced mesothelioma

Pembrolizumab monotherapy can achieve responses lasting for more than a year in some patients with previously treated malignant pleural mesothelioma (MPM), suggest phase 2 trial data.

26-04-2021 | Oncology | News | Article

EMA recommends extending osimertinib indication

Find out more about this decision here

20-04-2021 | Oncology | News | Article

Retreatment with tremelimumab–durvalumab feasible in mesothelioma patients

The NIBIT-MESO-1 trial suggests that retreatment with tremelimumab plus durvalumab could be a viable option for patients with unresectable mesothelioma who progress after initially benefiting from the combination.

Image Credits